Cargando…

Characteristics of procalcitonin in hospitalized COVID-19 patients and clinical outcomes of antibiotic use stratified by procalcitonin levels

We examined the characteristics of pro-calcitonin (PCT) in hospitalized COVID-19 patients (cohort 1) and clinical outcomes of antibiotic use stratified by PCT in non-critically ill patients without bacterial co-infection (cohort 2). Retrospective reviews were performed in adult, hospitalized COVID-1...

Descripción completa

Detalles Bibliográficos
Autores principales: So, Wonhee, Simon, Matthew S., Choi, Justin J., Wang, Tina Z., Williams, Samuel C., Chua, Jason, Kubin, Christine J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8916484/
https://www.ncbi.nlm.nih.gov/pubmed/35277828
http://dx.doi.org/10.1007/s11739-022-02955-5
_version_ 1784668307602800640
author So, Wonhee
Simon, Matthew S.
Choi, Justin J.
Wang, Tina Z.
Williams, Samuel C.
Chua, Jason
Kubin, Christine J.
author_facet So, Wonhee
Simon, Matthew S.
Choi, Justin J.
Wang, Tina Z.
Williams, Samuel C.
Chua, Jason
Kubin, Christine J.
author_sort So, Wonhee
collection PubMed
description We examined the characteristics of pro-calcitonin (PCT) in hospitalized COVID-19 patients (cohort 1) and clinical outcomes of antibiotic use stratified by PCT in non-critically ill patients without bacterial co-infection (cohort 2). Retrospective reviews were performed in adult, hospitalized COVID-19 patients during March–May 2020. For cohort 1, we excluded hospital transfers, renal disease and extra-pulmonary infection without isolated pathogen(s). For cohort 2, we further excluded microbiologically confirmed infection, ‘do not resuscitate ± do not intubate’ status, and intensive care unit (ICU). For cohort 1, PCT was compared between absent/low-suspicion and proven bacterial co-infections. Factors associated with elevated PCT and sensitivity/specificity/PPV/NPV of PCT cutoffs for identifying bacterial co-infections were explored. For cohort 2, clinical outcomes including mechanical ventilation within 5 days (MV5) were compared between the antibiotic and non-antibiotic groups stratified by PCT ≥ 0.25 µg/L. Nine hundred and twenty four non-ICU and 103 ICU patients were included (cohort 1). The median PCT was higher in proven vs. absent/low-suspicion of bacterial co-infection. Elevated PCT was significantly associated with proven bacterial co-infection, ICU status and oxygen requirement. For PCT ≥ 0.25 µg/L, sensitivity/specificity/PPV/NPV were 69/65/6.5/98% (non-ICU) and 75/33/8.6/94% (ICU). For cohort 2, 756/1305 (58%) patients were included. Baseline characteristics were balanced between the antibiotic and non-antibiotic groups except PCT ≥ 0.25 µg/L (antibiotic:non-antibiotic = 59%:24%) and tocilizumab use (antibiotic:non-antibiotic = 5%:2%). 23% (PCT < 0.25 µg/L) and 58% (PCT ≥ 0.25 µg/L) received antibiotics. Antibiotic group had significantly higher rates of MV5. COVID-19 severity inferred from ICU status and oxygen requirement as well as the presence of bacterial co-infections were associated with elevated PCT. PCT showed poor PPV and high NPV for proven bacterial co-infections. The use of antibiotics did not show improved clinical outcomes in COVID-19 patients with PCT ≥ 0.25 µg/L outside of ICU when bacterial co-infections are of low suspicion. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s11739-022-02955-5.
format Online
Article
Text
id pubmed-8916484
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-89164842022-03-14 Characteristics of procalcitonin in hospitalized COVID-19 patients and clinical outcomes of antibiotic use stratified by procalcitonin levels So, Wonhee Simon, Matthew S. Choi, Justin J. Wang, Tina Z. Williams, Samuel C. Chua, Jason Kubin, Christine J. Intern Emerg Med Im - Original We examined the characteristics of pro-calcitonin (PCT) in hospitalized COVID-19 patients (cohort 1) and clinical outcomes of antibiotic use stratified by PCT in non-critically ill patients without bacterial co-infection (cohort 2). Retrospective reviews were performed in adult, hospitalized COVID-19 patients during March–May 2020. For cohort 1, we excluded hospital transfers, renal disease and extra-pulmonary infection without isolated pathogen(s). For cohort 2, we further excluded microbiologically confirmed infection, ‘do not resuscitate ± do not intubate’ status, and intensive care unit (ICU). For cohort 1, PCT was compared between absent/low-suspicion and proven bacterial co-infections. Factors associated with elevated PCT and sensitivity/specificity/PPV/NPV of PCT cutoffs for identifying bacterial co-infections were explored. For cohort 2, clinical outcomes including mechanical ventilation within 5 days (MV5) were compared between the antibiotic and non-antibiotic groups stratified by PCT ≥ 0.25 µg/L. Nine hundred and twenty four non-ICU and 103 ICU patients were included (cohort 1). The median PCT was higher in proven vs. absent/low-suspicion of bacterial co-infection. Elevated PCT was significantly associated with proven bacterial co-infection, ICU status and oxygen requirement. For PCT ≥ 0.25 µg/L, sensitivity/specificity/PPV/NPV were 69/65/6.5/98% (non-ICU) and 75/33/8.6/94% (ICU). For cohort 2, 756/1305 (58%) patients were included. Baseline characteristics were balanced between the antibiotic and non-antibiotic groups except PCT ≥ 0.25 µg/L (antibiotic:non-antibiotic = 59%:24%) and tocilizumab use (antibiotic:non-antibiotic = 5%:2%). 23% (PCT < 0.25 µg/L) and 58% (PCT ≥ 0.25 µg/L) received antibiotics. Antibiotic group had significantly higher rates of MV5. COVID-19 severity inferred from ICU status and oxygen requirement as well as the presence of bacterial co-infections were associated with elevated PCT. PCT showed poor PPV and high NPV for proven bacterial co-infections. The use of antibiotics did not show improved clinical outcomes in COVID-19 patients with PCT ≥ 0.25 µg/L outside of ICU when bacterial co-infections are of low suspicion. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s11739-022-02955-5. Springer International Publishing 2022-03-11 2022 /pmc/articles/PMC8916484/ /pubmed/35277828 http://dx.doi.org/10.1007/s11739-022-02955-5 Text en © The Author(s), under exclusive licence to Società Italiana di Medicina Interna (SIMI) 2022 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle Im - Original
So, Wonhee
Simon, Matthew S.
Choi, Justin J.
Wang, Tina Z.
Williams, Samuel C.
Chua, Jason
Kubin, Christine J.
Characteristics of procalcitonin in hospitalized COVID-19 patients and clinical outcomes of antibiotic use stratified by procalcitonin levels
title Characteristics of procalcitonin in hospitalized COVID-19 patients and clinical outcomes of antibiotic use stratified by procalcitonin levels
title_full Characteristics of procalcitonin in hospitalized COVID-19 patients and clinical outcomes of antibiotic use stratified by procalcitonin levels
title_fullStr Characteristics of procalcitonin in hospitalized COVID-19 patients and clinical outcomes of antibiotic use stratified by procalcitonin levels
title_full_unstemmed Characteristics of procalcitonin in hospitalized COVID-19 patients and clinical outcomes of antibiotic use stratified by procalcitonin levels
title_short Characteristics of procalcitonin in hospitalized COVID-19 patients and clinical outcomes of antibiotic use stratified by procalcitonin levels
title_sort characteristics of procalcitonin in hospitalized covid-19 patients and clinical outcomes of antibiotic use stratified by procalcitonin levels
topic Im - Original
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8916484/
https://www.ncbi.nlm.nih.gov/pubmed/35277828
http://dx.doi.org/10.1007/s11739-022-02955-5
work_keys_str_mv AT sowonhee characteristicsofprocalcitonininhospitalizedcovid19patientsandclinicaloutcomesofantibioticusestratifiedbyprocalcitoninlevels
AT simonmatthews characteristicsofprocalcitonininhospitalizedcovid19patientsandclinicaloutcomesofantibioticusestratifiedbyprocalcitoninlevels
AT choijustinj characteristicsofprocalcitonininhospitalizedcovid19patientsandclinicaloutcomesofantibioticusestratifiedbyprocalcitoninlevels
AT wangtinaz characteristicsofprocalcitonininhospitalizedcovid19patientsandclinicaloutcomesofantibioticusestratifiedbyprocalcitoninlevels
AT williamssamuelc characteristicsofprocalcitonininhospitalizedcovid19patientsandclinicaloutcomesofantibioticusestratifiedbyprocalcitoninlevels
AT chuajason characteristicsofprocalcitonininhospitalizedcovid19patientsandclinicaloutcomesofantibioticusestratifiedbyprocalcitoninlevels
AT kubinchristinej characteristicsofprocalcitonininhospitalizedcovid19patientsandclinicaloutcomesofantibioticusestratifiedbyprocalcitoninlevels